Malek Meskawi1, Pierre-Alain Hueber1, Roger Valdivieso1, Franck Bruyere2, Vincent Misrai3, Georges Fournier4, Ravi Munver5, Ganesh Sivarajan5, Matthew Rutman6, Alexis E Te7, Bilal Chughtai7, Dean Elterman8, Tristan Martel1, Mounsif Azizi1, Pierre I Karakiewicz1, Kevin C Zorn9. 1. Department of Urology, University of Montreal Hospital Center (CHUM), Montréal, QC, Canada. 2. Department of Urology, CHU Tours, Tours, France. 3. Department of Urology, Clinique Pasteur Toulouse, Toulouse, France. 4. Department of Urology, CHU Brest, Brest, France. 5. Department of Urology, Hackensack University, Hackensack, USA. 6. Department of Urology, Columbia University, New York City, USA. 7. Department of Urology, Cornell University, New York City, USA. 8. Department of Urology, University of Toronto, Toronto, Canada. 9. Department of Urology, University of Montreal Hospital Center (CHUM), Montréal, QC, Canada. zorn.chumurology@gmail.com.
Abstract
PURPOSE: To evaluate the outcomes and durability of photoselective vaporization of the prostate (PVP) using the XPS-180 system in patients with a large prostate volume (PV) > 100 cc at 4 years of follow-up in a large, multicenter experience. METHODS: 438 men with pre-operative transrectal ultrasound (TRUS) PV > 100 cc were treated in eight experienced centers in Canada, USA, and in France with the Greenlight XPS laser using PVP for the treatment of symptomatic BPH. IPSS, Qmax, postvoid residual (PVR), and prostate-specific antigen (PSA) were measured at 6, 12, 24, 36, and 48 months. Durability was evaluated using BPH retreatment rate at 12, 24, and 36 months. RESULTS: Median PV and PSA were 121 cc and 6.3 ng/dl. Indwelling catheter at the time of surgery was observed in 37% of men. Median operative, laser time, and energy applied were 90 min, 55 min, and 422 kJ, respectively. Median energy delivery was 3.4 kJ/cc of prostate per case. Outpatient surgery was feasible with median length of stay at 24 h. IPSS, Qmax and PVR were significantly improved at all endpoints including at 48 months. Moreover, surgical BPH retreatment rates were 5.4 and 9.3% at 24 and 36 months. Interestingly, characteristics of retreated men include: energy delivery 2.4 vs. 3.4 kJ/cc of prostate (p = 0.02) and PSA reduction at 12 months 26 vs. 51% (p = 0.02). CONCLUSIONS: PVP using Greenlight XPS-180W can potentially provide durable improvements with regard to functional outcomes at 4 years. However, rising retreatment rates after 3 years is of concern. This highlights the imperative need of utilizing a standardized surgical technique (enucleation-like-defect) and an optimal energy density >3KJ/cc.
PURPOSE: To evaluate the outcomes and durability of photoselective vaporization of the prostate (PVP) using the XPS-180 system in patients with a large prostate volume (PV) > 100 cc at 4 years of follow-up in a large, multicenter experience. METHODS: 438 men with pre-operative transrectal ultrasound (TRUS) PV > 100 cc were treated in eight experienced centers in Canada, USA, and in France with the Greenlight XPS laser using PVP for the treatment of symptomatic BPH. IPSS, Qmax, postvoid residual (PVR), and prostate-specific antigen (PSA) were measured at 6, 12, 24, 36, and 48 months. Durability was evaluated using BPH retreatment rate at 12, 24, and 36 months. RESULTS: Median PV and PSA were 121 cc and 6.3 ng/dl. Indwelling catheter at the time of surgery was observed in 37% of men. Median operative, laser time, and energy applied were 90 min, 55 min, and 422 kJ, respectively. Median energy delivery was 3.4 kJ/cc of prostate per case. Outpatient surgery was feasible with median length of stay at 24 h. IPSS, Qmax and PVR were significantly improved at all endpoints including at 48 months. Moreover, surgical BPH retreatment rates were 5.4 and 9.3% at 24 and 36 months. Interestingly, characteristics of retreated men include: energy delivery 2.4 vs. 3.4 kJ/cc of prostate (p = 0.02) and PSA reduction at 12 months 26 vs. 51% (p = 0.02). CONCLUSIONS: PVP using Greenlight XPS-180W can potentially provide durable improvements with regard to functional outcomes at 4 years. However, rising retreatment rates after 3 years is of concern. This highlights the imperative need of utilizing a standardized surgical technique (enucleation-like-defect) and an optimal energy density >3KJ/cc.
Entities:
Keywords:
>100 cc; Benign prostate hyperplasia; Greenlight; Large prostate; Photoselective vaporization of the prostate; XPS
Authors: Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei Journal: J Urol Date: 2011-03-21 Impact factor: 7.450
Authors: Ahmed M Elshal; Mohamed A Elkoushy; Ahmed R El-Nahas; Ahmed M Shoma; Adel Nabeeh; Serge Carrier; Mostafa M Elhilali Journal: J Urol Date: 2014-09-28 Impact factor: 7.450
Authors: Alexander Bachmann; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; J Andrew Thomas Journal: Eur Urol Date: 2013-11-11 Impact factor: 20.096
Authors: William W Tinmouth; Enmar Habib; Samuel C Kim; Ramsay L Kuo; Ryan F Paterson; Colin L Terry; Mostafa Elhilali; James E Lingeman Journal: J Endourol Date: 2005-06 Impact factor: 2.942
Authors: Christian Gratzke; Alexander Bachmann; Aurelien Descazeaud; Marcus J Drake; Stephan Madersbacher; Charalampos Mamoulakis; Matthias Oelke; Kari A O Tikkinen; Stavros Gravas Journal: Eur Urol Date: 2015-01-19 Impact factor: 20.096
Authors: Roger Valdivieso; Christian P Meyer; Pierre-Alain Hueber; Malek Meskawi; Abdullah M Alenizi; Mounsif Azizi; Quoc-Dien Trinh; Vincent Misrai; Matthew Rutman; Alexis E Te; Bilal Chughtai; Neil J Barber; Amr M Emara; Ravi Munver; Kevin C Zorn Journal: BJU Int Date: 2016-04-16 Impact factor: 5.588
Authors: Alexander Bachmann; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; J Andrew Thomas Journal: J Urol Date: 2014-09-16 Impact factor: 7.450
Authors: Benoit Peyronnet; Vincent Misrai; Tev Aho; Henry Woo; Thomas Herrmann; Fernando Gomez-Sancha Journal: World J Urol Date: 2017-04-28 Impact factor: 4.226
Authors: Vincent Misraï; Marie Pasquie; Benoit Bordier; Benjamin Elman; Jean Michel Lhez; Julien Guillotreau; Kevin Zorn Journal: World J Urol Date: 2018-01-25 Impact factor: 4.226
Authors: Luca Cindolo; Cosimo De Nunzio; Francesco Greco; Paolo Destefanis; Franco Bergamaschi; Giovanni Ferrari; Giuseppe Fasolis; Fabiano Palmieri; Claudio Divan; Rino Oriti; Lorenzo Ruggera; Andrea Tubaro; Claudio Dadone; Gaetano De Rienzo; Antonio Frattini; Vincenzo Mirone; Luigi Schips Journal: World J Urol Date: 2017-11-01 Impact factor: 4.226
Authors: Kevin C Zorn; S Larry Goldenberg; Ryan Paterson; Alan So; Dean Elterman; Naeem Bhojani Journal: Can Urol Assoc J Date: 2018-10-15 Impact factor: 1.862
Authors: David-Dan Nguyen; Neil Barber; Mo Bidair; Peter Gilling; Paul Anderson; Kevin C Zorn; Gopal Badlani; Mitch Humphreys; Steven Kaplan; Ronald Kaufman; Alan So; Ryan Paterson; Larry Goldenberg; Dean Elterman; Mihir Desai; Jim Lingeman; Claus Roehrborn; Naeem Bhojani Journal: Eur Urol Open Sci Date: 2021-01-31